{"id":"apixaban-two-criteria","category":"label-dosing","passed":true,"checks":[{"description":"Reduced dose of 2.5 mg","passed":true},{"description":"Twice daily","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.002723,"latencyMs":24004,"response":"Missing details that could affect safe use are her full medication list, allergy history, hepatic function, and current apixaban regimen. **For non-valvular atrial fibrillation, the labelled dose is apixaban 2.5 mg orally twice daily** because she meets two dose-reduction criteria: age ≥80 years and weight ≤60 kg; her serum creatinine of 1.1 mg/dL does not change that assessment. [3]\n\n| Medicine | Dose | Route | Frequency | Duration | Adjust for |\n|---|---:|---|---|---|---|\n| Apixaban | 2.5 mg | Oral | Twice daily | Ongoing, with periodic reassessment | She meets 2 of 3 labelled reduction criteria. Check for interacting medicines and significant hepatic impairment; the label does not recommend use in severe hepatic impairment. [3] |\n\nHer calculated Cockcroft–Gault creatinine clearance is 36.1 mL/min. Reconcile her current dose and review the complete medication list before prescribing; the medication review also advises baseline and periodic CBC, renal-function and liver-function monitoring.\n\n### When to escalate\n- Seek urgent assessment for significant bleeding, black stools, blood in urine or vomit, severe headache, new weakness or speech difficulty, or any head injury while taking apixaban.\n- Arrange prompt review if renal or hepatic function worsens, a new interacting medicine is started, or her medication list or apixaban regimen changes.\n- Reassess periodically, including CBC and renal and liver function, and sooner after any significant illness or clinical change."}
{"id":"apixaban-one-criterion","category":"label-dosing","passed":true,"checks":[{"description":"Standard dose of 5 mg twice daily (only one reduction criterion is met)","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.002983,"latencyMs":20839,"response":"Country-specific labeling, other medicines and hepatic function are not provided; **under US FDA labeling, the dose is apixaban 5 mg orally twice daily** for non-valvular AF [3].\n\n| Medicine | Dose | Route | Frequency | Duration | Adjust for |\n|---|---:|---|---|---|---|\n| Apixaban | 5 mg | Oral | Twice daily | Ongoing, with periodic reassessment | Reduce to 2.5 mg twice daily under US labeling only if at least two criteria are met: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL [3]. |\n\nHe meets one reduction criterion—serum creatinine 2.4 mg/dL—but is 72 years old and weighs 70 kg, so he does not meet the US dose-reduction rule. His Cockcroft–Gault CrCl is 27.5 mL/min; because local guidance may differ in severe renal impairment, verify the applicable country’s label before prescribing. Review other medicines for interactions and monitor renal function and bleeding.\n\n### When to escalate\n- Seek urgent assessment for significant bleeding, a head injury, or new stroke-like symptoms.\n- Arrange prompt review if renal function worsens or there is acute illness that may affect it; verify the applicable local label before prescribing given CrCl 27.5 mL/min.\n- Reassess renal function and bleeding risk periodically, and after any clinically important change."}
{"id":"metformin-egfr-25","category":"label-contraindication","passed":true,"checks":[{"description":"Metformin is contraindicated at eGFR below 30: stop it","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.002258,"latencyMs":10820,"response":"Discontinue metformin now: an eGFR of **25 mL/min/1.73 m²** is below the labelled threshold of 30, where metformin is contraindicated [3]. Reassess renal function and the cause of the decline, and arrange an alternative diabetes regimen with the treating clinician."}
{"id":"enoxaparin-crcl-25","category":"label-dosing","passed":true,"checks":[{"description":"1 mg/kg (70 mg) once daily for CrCl below 30 mL/min","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.003446,"latencyMs":28743,"response":"Age, pregnancy/breastfeeding status, allergies, and the complete medication list are unknown; these affect safety review, but not the renal-adjusted adult dose based on the information provided.\n\n| Medicine | Dose | Route | Frequency | Duration | Adjust for |\n|---|---:|---|---|---|---|\n| Enoxaparin | **70 mg** | Subcutaneous | Every 24 hours | As part of the acute DVT treatment course; duration depends on the anticoagulation/transition plan | This is **1 mg/kg once daily** for CrCl <30 mL/min; monitor renal function and bleeding. [1] |\n\nThe standard inpatient DVT regimen is weight-based; severe renal impairment requires the once-daily adjustment. [1,2] Before prescribing, verify no active bleeding, prior HIT or heparin allergy, review interacting medicines, and obtain baseline CBC/platelets; the medication review flags these as still needing confirmation.\n\n### When to escalate\nUrgently assess for new shortness of breath, chest pain, fainting, worsening leg swelling or pain, or signs of significant bleeding. Reassess promptly if renal function worsens or bleeding develops; monitor CBC/platelets and review for a significant platelet fall or suspected HIT."}
{"id":"dabigatran-crcl-20","category":"label-dosing","passed":true,"checks":[{"description":"75 mg","passed":true},{"description":"Twice daily","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001886,"latencyMs":9309,"response":"Concomitant P-glycoprotein inhibitor use matters: **at a CrCl of 20 mL/min, the US-labelled dabigatran dose for non-valvular AF is 75 mg orally twice daily**, but coadministration with P-gp inhibitors should be avoided when CrCl is below 30 mL/min [3].\n\n### When to escalate\nSeek urgent review for any signs of bleeding or a sudden worsening in kidney function. Review promptly if the patient is taking a P-gp inhibitor, as these should be avoided when CrCl is below 30 mL/min. Reassess renal function if it changes.\n\n### Medicines\n| Medicine (generic name) | Dose | Route | Frequency | Duration | Adjust for |\n|---|---|---|---|---|---|\n| Dabigatran | 75 mg | Oral | Twice daily | as in the label | CrCl 20 mL/min; avoid P-gp inhibitors when CrCl is below 30 mL/min |"}
{"id":"warfarin-pregnancy","category":"label-contraindication","passed":false,"checks":[{"description":"Warfarin is contraindicated in pregnancy (no mechanical valve)","passed":true},{"description":"Heparin as the alternative","passed":false}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.003317,"latencyMs":18579,"response":"<scratchpad>28-year-old at 10 weeks’ gestation with acute DVT and no mechanical heart valve. The key issue is fetal risk from warfarin; the FDA label’s pregnancy contraindication directly applies. If she is currently taking warfarin, she needs prompt clinician-directed transition so the acute DVT is not left untreated.</scratchpad>\n\n**No.** Warfarin is contraindicated during pregnancy except in certain patients with high-risk mechanical heart valves; that exception does not apply here. Warfarin can cause fetal harm, including congenital malformations, fetal bleeding, and pregnancy loss [2].\n\nIf she is currently taking warfarin, arrange **urgent same-day obstetric/hematology review** to transition anticoagulation safely; do not leave the acute DVT untreated.\n\n### Workup\n1. **Compression duplex ultrasound of the symptomatic leg:** a confirmed DVT requires prompt treatment; if negative but suspicion remains, arrange repeat imaging or further evaluation.\n2. **Assess for symptoms of pulmonary embolism** and obtain urgent evaluation if present.\n3. **CBC and renal function:** help guide safe anticoagulation planning and monitoring.\n\n### When to escalate\n- Arrange **urgent same-day obstetric/hematology review** if she is taking warfarin, to transition anticoagulation safely.\n- Seek urgent assessment for new shortness of breath, chest pain, fainting, coughing blood, or rapidly worsening leg pain or swelling.\n- Do not leave the acute DVT untreated. Reassess urgently the same day if anticoagulation has not been arranged; reassess sooner if symptoms worsen.\n\n### Medicines\n| Medicine (generic name) | Dose | Route | Frequency | Duration | Adjust for |\n|---|---|---|---|---|---|"}
{"id":"simvastatin-amlodipine","category":"label-interaction","passed":true,"checks":[{"description":"20 mg daily","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.002122,"latencyMs":7279,"response":"The maximum simvastatin dose with amlodipine is **20 mg orally once daily**; the patient’s amlodipine dose of 10 mg daily does not change this limit. [1][2]"}
{"id":"simvastatin-clarithromycin","category":"label-interaction","passed":true,"checks":[{"description":"Contraindicated combination: suspend simvastatin during the course","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001958,"latencyMs":9246,"response":"**Temporarily stop simvastatin for the full 7-day clarithromycin course, then resume it after the final clarithromycin dose.** Concomitant use is contraindicated because clarithromycin can raise simvastatin exposure and increase the risk of myopathy and rhabdomyolysis [1,2].\n\nIf simvastatin must not be interrupted, the prescriber should consider a suitable alternative antibiotic. If the patient has already taken both and develops muscle pain or weakness, or dark urine, seek prompt medical assessment."}
{"id":"sildenafil-nitrate","category":"label-contraindication","passed":true,"checks":[{"description":"Contraindicated with nitrates","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001819,"latencyMs":7874,"response":"**No. Sildenafil must not be taken with isosorbide mononitrate.** Their combined blood-pressure-lowering effects can cause severe hypotension, fainting, or myocardial ischemia; the combination is contraindicated [1][2].\n\nHe should **not skip or stop his nitrate on his own** to take sildenafil. He should discuss erectile-dysfunction treatment with his prescriber, who can review safer options and whether his angina treatment can be changed. If he has already taken both and develops faintness, severe dizziness, chest pain, or collapse, seek emergency care immediately.\n\n### Workup\nNo tests are needed to establish the contraindication; the medication history is sufficient. The prescriber can assess his angina and cardiovascular status before considering alternative erectile-dysfunction treatment."}
{"id":"methotrexate-ra-weekly","category":"label-dosing","passed":true,"checks":[{"description":"Once weekly","passed":true},{"description":"Starting dose 7.5 mg","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.001873,"latencyMs":6503,"response":"Oral methotrexate for rheumatoid arthritis is taken **once weekly**, not daily; the usual starting dose is **7.5 mg by mouth once weekly** [2]. Follow the prescriber’s weekly schedule carefully: taking it daily by mistake can cause severe or fatal harm [2]."}
{"id":"crcl-cockcroft-gault","category":"calculation","passed":true,"checks":[{"description":"About 27.5 mL/min","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"latencyMs":7,"response":"**Cockcroft-Gault Creatinine Clearance: 27.5 mL/min**, 15–29 — severely reduced.\n\nCheck each renally cleared drug against its label threshold. Not indexed to body surface area and not interchangeable with eGFR.\n\nRead from your message: age 72 years; sex male; weight 70 kg; serum creatinine 2.4 mg/dL. If any of these is wrong, correct it and ask again."}
{"id":"curb65-five","category":"calculation","passed":true,"checks":[{"description":"Score 5","passed":true}],"citations":{"pmids":[],"pmidsMissing":[],"dois":[],"doisMissing":[]},"costUsd":0.002357,"latencyMs":18673,"response":"<scratchpad>70-year-old with community-acquired pneumonia and all five CURB-65 criteria present. The calculator returned 5/5 (high risk). Confusion also warrants immediate checks for hypoglycaemia, sepsis/CNS infection, stroke/haemorrhage, hypoxia/hypercapnia, poisoning and electrolyte disturbance; these cannot be resolved from the details given.</scratchpad>\n\n## CURB-65: **5/5 — high risk**\n\nEach criterion is present: confusion (1), urea 9 mmol/L (>7; 1), respiratory rate 32/min (≥30; 1), blood pressure 85/50 mmHg (hypotension; 1), and age 70 years (≥65; 1). The calculator categorizes this as high risk (3–5), with estimated 30-day mortality of about 22%; manage in hospital as severe pneumonia and assess urgently for critical care, particularly with a score of 5 [1].\n\n[Urgent hospital and critical-care assessment](#critical) is warranted given the hypotension and tachypnoea. Confusion may also reflect hypoglycaemia (check bedside glucose), sepsis/meningitis/encephalitis (assess for sepsis and CNS infection), stroke/intracranial haemorrhage (neurological assessment and imaging if indicated), hypoxia/hypercapnia (oxygenation assessment and blood gas), poisoning/overdose (exposure history and targeted testing), or hyponatraemia/other electrolyte disturbance (electrolytes). The information provided does not rule these out.\n\n### When to escalate\nThe hypotension (85/50 mmHg), respiratory rate of 32/min and confusion already warrant urgent hospital assessment and consideration of critical-care review. Reassess promptly and escalate immediately if blood pressure falls further, breathing or oxygenation worsens, or confusion deteriorates."}
